Genmab Has First Wholly Owned Antibodies In Phase III, Hunts For More
Shifting From Out-Licensing To Retaining Assets
CMO Tahamtan Ahmadi told Scrip that Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.
